Genomic epidemiology of acute respiratory distress syndrome and fibrosis in patients with COVID-19

COVID-19 is a respiratory illness caused by a virus spread worldwide. Some patients with severe COVID-19 develop deadly lung conditions, such as acute respiratory distress syndrome (ARDS) and lung scarring (termed 'pulmonary fibrosis' [PF]). These conditions can lead to death or to long-term reduced quality of life of patients. Currently, there are no specific treatments or effective methods for predicting how ARDS or PF will progress, and therefore further studies are needed to better understand these fatal conditions. As genetics are known to influence susceptibility of ARDS and PF, we will study the DNA of COVID-19 patients by means of state-of-the-art genetic methods. I aim to identify those patients at higher risk of ARDS and PF and to reveal specific genes and biological processes that drive that increased risk. The findings will inform improved and more personalised care and will help identify new treatment options for patients with these conditions.